Engflag

Adenosine Triphosphate

Quick links to important sections

Adenosine Triphosphate

Adenosine Triphosphate_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Adenosine Triphosphate

Understanding Adenosine Triphosphate (ATP)

Adenosine Triphosphate, commonly referred to as ATP, is a complex organic chemical that provides energy to drive many processes in living cells. Often described as the "molecular unit of currency" of intracellular energy transfer, it is found in all forms of life.

Chemical Structure

ATP consists of three main components:

  • Adenine: A nitrogenous base.
  • Ribose: A five-carbon sugar.
  • Phosphate Groups: A chain of three phosphate groups linked to the ribose.

The energy held within ATP is stored in the chemical bonds between these phosphate groups. When the cell requires energy, the bond between the second and third phosphate groups is broken through a process called hydrolysis.

Biological Function

ATP plays a critical role in various physiological functions, acting as a primary energy source for biological reactions. Its responsibilities include:

  • Muscle Contraction: Providing the energy necessary for muscle fibers to shorten and create movement.
  • Nerve Signaling: Assisting in the transport of ions across cell membranes to facilitate the transmission of nerve impulses.
  • Chemical Synthesis: Powering the creation of complex molecules such as proteins, DNA, and RNA.
  • Active Transport: Moving substances across cell membranes against a concentration gradient.

Production in the Body

Cells generate ATP through several metabolic pathways. The most prominent method is cellular respiration, which occurs in the mitochondria—the specialized structures within cells often called the powerhouses of the cell. During this process, the body converts nutrients from food, such as glucose and fats, into usable ATP.

When ATP is used, it loses a phosphate group and becomes Adenosine Diphosphate (ADP). Through further metabolic processes, the body adds a phosphate group back to ADP, effectively "recharging" the molecule to be used as ATP once again.

Regulatory References

  1. Physiology, Adenosine Triphosphate - StatPearls - NCBI Bookshelf

What side effects are possible with Adenosine Triphosphate?

Possible Side Effects and Safety Information

The safety profile for Adenosine Triphosphate (ATP), or its administered form adenosine, is characterized by adverse reactions that are typically transient and short-lived, reflecting the molecule's ultra-short half-life and rapid metabolism. Regulatory agencies organize these effects primarily across the Cardiac, Vascular, and Respiratory system-organ classes.

Most reported adverse reactions occur immediately upon administration and are classified by frequency in official documentation:

Frequency Classification Examples of Listed Adverse Reactions
Very Common (ge 10%) Flushing, chest discomfort or pressure, shortness of breath (dyspnea), headache, throat/neck/jaw discomfort.
Common (1% to 10%) Nausea, paresthesia (tingling/numbness), nervousness, apprehension.

Serious adverse reactions, though rare, are documented in official prescribing information. These include life-threatening events such as transient episodes of asystole (cardiac arrest), ventricular fibrillation, myocardial infarction (MI), and respiratory arrest. These serious events define the drug's maximal potential risk and necessitate use in closely monitored settings.

Safety restrictions are explicitly listed in regulatory documents. The medicine is contraindicated in patients with pre-existing conditions such as Second- or Third-Degree Atrioventricular (AV) Block or Sick Sinus Syndrome (unless a functioning artificial pacemaker is present), and in patients with known or suspected bronchospastic lung disease (e.g., asthma). Co-administration with certain substances, such as dipyridamole, may potentiate its vasoactive effects, increasing the risk of adverse events.

Overdose and Emergency Response

An overdose of Adenosine Triphosphate is defined in regulatory labeling as the administration of doses or injection volumes that substantially exceed the recommended therapeutic levels, resulting in an exaggeration of its known pharmacological effects on the cardiovascular system. Documented clinical manifestations of overdose include persistent severe bradycardia, prolonged atrioventricular (AV) block, and profound hypotension. Severe or life-threatening outcomes such as sustained cardiac arrest and prolonged asystole have been reported.

Due to the ultra-short half-life of the substance, the primary mandated emergency action is the immediate discontinuation of Adenosine Triphosphate administration. Regulatory documents confirm that no specific pharmacological antidote is known, and the effects of overdose are generally expected to be self-limiting as the substance is rapidly metabolized. Management is strictly symptomatic and supportive, which may involve the use of measures such as volume expansion, vasopressors, or cardiac pacing for severe, persistent symptoms. Continuous ECG and blood pressure monitoring is required until all manifestations fully resolve. Immediate medical attention or contact with emergency services is required for any severe or prolonged symptoms, especially those related to cardiac arrest or sustained hypotension.

Therapeutic Uses of Adenosine Triphosphate

Quick Facts

  • Indicated for conversion: Assists in the transition to a normal heart rhythm from paroxysmal supraventricular tachycardia (PSVT).
  • Diagnostic use: Employed as a pharmacological stress agent in patients who are unable to undergo adequate physical exercise for myocardial perfusion imaging.

What Adenosine Triphosphate Treats: Main Uses and Benefits

Adenosine Triphosphate (ATP) is utilized in clinical settings primarily in a therapeutic and diagnostic capacity related to cardiovascular function. The therapeutic application of the medication involves addressing certain types of rapid heart rhythm irregularities, specifically to facilitate the restoration of a regular heart rhythm in individuals experiencing paroxysmal supraventricular tachycardia (PSVT). This medical intervention is designed to stabilize the heart's electrical activity.

In a diagnostic context, the medication is administered to support specific tests used to assess the heart. It functions as a pharmacologic stress agent, often in conjunction with imaging studies, for patients who are restricted from performing sufficient physical exercise. This approach helps healthcare providers obtain necessary information for the diagnosis of coronary artery disease. Furthermore, clinical observation indicates that Adenosine Triphosphate may support the management of involuntary weight loss (cachexia) associated with certain advanced cancers, potentially contributing to improved appetite and quality of life.

Eligibility and Restrictions for Use

Who can and cannot use Adenosine Triphosphate

This medication is primarily used in hospital settings for specific cardiac diagnostic or therapeutic procedures. Eligibility to receive Adenosine Triphosphate is strictly defined by regulatory guidelines based on a patient's pre-existing conditions and physiological state.

Contraindicated Populations

Adenosine Triphosphate must not be used in patients with the following conditions, as use could lead to serious adverse effects:

  • Second- or third-degree atrioventricular (AV) block or sinus node disease (such as sick sinus syndrome or symptomatic bradycardia), unless the patient has a fully functioning artificial pacemaker.
  • Known hypersensitivity or allergy to adenosine.
  • Known or suspected bronchoconstrictive or bronchospastic lung disease, such as asthma.

Populations Requiring Caution or Special Consideration

Use of this medicine requires caution in several patient groups, including:

  • Geriatric patients due to potentially diminished cardiac function.
  • Patients with pre-existing first-degree AV block or bundle branch block.
  • Individuals with conditions that increase the risk of severe hypotension, such as hypovolemia or stenotic valvular heart disease.
  • Use is avoided in patients showing signs or symptoms of acute myocardial ischemia.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Adenosine Triphosphate (ATP) is determined by its function as a purine nucleoside and is based strictly on regulatory-documented patterns, requiring specific management when co-administered with other substances.

Documented Interaction Classes

Interaction Entity Mechanism Described in Label Restriction Type
Dipyridamole Nucleoside transport inhibition Contraindicated/Timing Separation
Methylxanthines Competitive receptor antagonism Timing Separation Required
Cardioactive Drugs Additive depressant effects Caution Advised

The most significant restriction involves Dipyridamole and similar nucleoside transport inhibitors. These agents block the uptake and metabolism of Adenosine, potentiating its effects, and co-administration is generally not recommended unless Dipyridamole is stopped 24 hours beforehand. Conversely, substances containing Methylxanthines (e.g., Theophylline, Aminophylline) act as competitive antagonists at the adenosine receptor. This antagonism can reduce the medicine's effectiveness, necessitating that these drugs be avoided for 24 hours prior to administration.

Regulatory documentation also notes that Cardioactive Drugs (such as beta-blockers and calcium channel blockers) may exert an additive depressant effect on the heart's conduction nodes. Furthermore, xanthine-containing foods and drinks (like coffee or cola) must be avoided for at least 12 hours due to their antagonistic properties. Specific population cautions include the observed increased sensitivity to Adenosine in recent heart transplant recipients.

Mechanism of Action

How Adenosine Triphosphate Works

Dual Mechanism: Direct Receptor Activation and Rapid Conversion

This mechanism involves two stages: the drug first directly activates P2X and P2Y purinergic receptors on blood vessels, initiating a cascade that leads to the widening of these vessels. Immediately following this, the drug is broken down by enzymes into adenosine, which then acts as an agonist on a separate target, the A1 receptors, to influence the heart's electrical signals.

Modulating Cardiac Electrical Conduction

The rapid conversion of the drug into adenosine is essential for its primary physiological effect on the heart. Adenosine activates A1 receptors within the atrioventricular (AV) node, which is the critical electrical relay center of the heart. This action slows the speed of electrical impulse transmission through the AV node, producing a transient reduction in the velocity of electrical signal propagation.

Regulating Vascular Tone and Systemic Resistance

Independently of its effect on the heart, the drug directly binds to P2Y receptors on the inner lining of blood vessels. This binding triggers the release of signaling molecules like nitric oxide, leading to the relaxation of surrounding smooth muscle. This mechanistic domain contributes to a transient decrease in systemic vascular resistance.

Dosage and Administration Information

How to Use Adenosine Triphosphate

The administration of Adenosine Triphosphate (ATP) is categorized into two primary modes of use: acute rhythm control and diagnostic stress testing. The medicine is supplied exclusively as a sterile solution for parenteral administration, reflecting its ultra-short duration of action.

Administration Protocols

Use Case Route, Dosing, and Timing Procedural Conditions
Acute Rhythm Control Administered as a rapid Intravenous (IV) Bolus. The initial adult dose is typically 6 mg. If conversion is not achieved within 1 to 2 minutes, a second dose of 12 mg may be given, followed by a final 12 mg dose if needed. The IV bolus must be administered over 1 to 2 seconds and immediately followed by a rapid 20 mL normal saline flush. The injection site should be as close as possible to the central circulation to ensure rapid delivery.
Diagnostic Stress Testing Administered as a Continuous Peripheral IV Infusion at a fixed rate of 0.14 mg/kg/min. The total course of administration is exactly six minutes. The diagnostic agent (radioisotope) must be injected at the midpoint of the infusion (after three minutes) to align with standardized stress protocols.

Population and Procedural Adjustments

Specific dosing rules apply to certain patient groups. For pediatric patients (those under 50 kg), the PSVT dose is determined by weight, starting at 0.05 to 0.1 mg/kg. Furthermore, the initial dose may be reduced (e.g., to 3 mg) when administered via a central venous line or to individuals with a heart transplant. The solution must always be visually inspected and must not be administered if any particulate matter or discoloration is present.

Recent Clinical Evidence

Research evidence / Overview of studies for Adenosine Triphosphate

This overview describes the types of scientific research conducted on Adenosine Triphosphate, including the study designs, the patient groups examined, and the areas where data remains limited or ongoing, based only on reports from regulatory bodies and peer-reviewed literature.

Evidence for Use in Converting Paroxysmal Supraventricular Tachycardia (PSVT)

Research for PSVT primarily involves Randomized Controlled Trials (RCTs) and controlled clinical observations focused on adults. Studies monitored the electrical activity of the heart, reporting the frequency of conversion to a normal rhythm and the time required for this transition. The research is largely focused on the immediate, acute setting due to the compound's ultra-short duration of action.

Evidence for Use as a Diagnostic Stress Agent

ATP has been evaluated in observational cohort studies and specialized diagnostic accuracy trials for its role as a pharmacological stress agent in heart imaging (MPI). These studies were applied to adults with suspected blockages who could not exercise, finding patterns of diagnostic findings that were evaluated against certain other agents used in these stress tests.

Evidence for Supportive Use in Cancer-Associated Cachexia

Research for supportive use involved RCTs focused on adults with advanced non-small cell lung cancer experiencing cachexia. Studies examined outcomes related to body weight changes, muscle strength, and patient-reported Quality of Life (QOL). Some trials reported differences in these outcomes when comparing the observed groups. This research is highly specific to this particular cancer population.

Research Gaps and Areas of Uncertainty

Scientific literature consistently highlights limitations, including that long-term effects are not fully established for supportive care, with follow-up durations being limited in many of the key studies. Data for certain patient groups, such as children or those with complex co-existing medical conditions, remains less frequent. The evidence quality varies across studies, and research examining comparative study designs against all other acute interventions is not fully established.

Frequently Asked Questions (FAQ)

Common questions about Adenosine Triphosphate (FAQ)

Q: How long does the effect of Adenosine Triphosphate last on the body?

According to official product information, the active substance, Adenosine, has an extremely short half-life—typically less than 10 seconds—in whole blood. Due to this rapid clearance, its effects are generally described in regulatory information as self-limiting.

Q: What serious side effects should I be worried about?

Regulatory documents indicate that this medicine carries a risk of serious, life-threatening events, and its use requires close medical monitoring. The documented severe risks include transient episodes of asystole (a brief absence of heartbeat), ventricular fibrillation, myocardial infarction (MI or heart attack), and respiratory arrest.

Q: Can I take Adenosine Triphosphate with my beta-blocker?

Official information advises caution when Adenosine Triphosphate is given to a patient who has also received other heart medicines, such as beta-blockers. This is due to a risk that the combination may lead to additive depressant effects on the heart’s electrical conduction system. It is noted that this potential interaction is a caution point for medical professionals managing the procedure.

Q: Can I use a partially used vial later?

The injection vials for this medicine contain no preservative and are explicitly labeled as single-dose vials. For safety and sterility, all official product handling instructions state that any unused portion of the solution should be discarded after the injection is prepared or administered.

How should Adenosine Triphosphate be stored and disposed of?

How to Store and Dispose of Adenosine Triphosphate (ATP) Injection

Adenosine Triphosphate (ATP) Injection requires specific handling to maintain its quality and potency, as directed by official regulatory labeling.

Storage Requirements

Condition Requirement
Temperature Store under refrigeration, maintained between 2°C and 8°C (36°F and 46°F).
Freezing The product must not be frozen as this can compromise the sterile solution.
Protection Keep the medicine in its original container until use and store it out of the sight and reach of children.

Disposal Instructions

Disposal of any unused medication or waste material must be carried out in accordance with local requirements. The product should generally not be disposed of via household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Adenosine Triphosphate found in:

A-Z Index: